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Anti-inflammatory activity
of electron-deficient
organometallics
Jingwen Zhang, Anaïs Pitto-Barry, Lijun Shang and
Nicolas P. E. Barry
School of Chemistry and Biosciences, University of Bradford, Bradford BD7 1DP, UK
NPEB, 0000-0002-0388-6295
We report an evaluation of the cytotoxicity of a series of
electron-deficient (16-electron) half-sandwich precious metal
complexes of ruthenium, osmium and iridium ([Os/Ru(η6-p-
cymene)(1,2-dicarba-closo-dodecarborane-1,2-dithiolato)] (1/2),
[Ir(η5-pentamethylcyclopentadiene)(1,2-dicarba-closo-dodecar-
borane-1,2-dithiolato)] (3), [Os/Ru(η6-p-cymene)(benzene-1,
2-dithiolato)] (4/5) and [Ir(η5-pentamethylcyclopentadiene)
(benzene-1,2-dithiolato)] (6)) towards RAW 264.7 murine
macrophages and MRC-5 fibroblast cells. Complexes 3 and
6 were found to be non-cytotoxic. The anti-inflammatory
activity of 1–6 was evaluated in both cell lines after nitric
oxide (NO) production and inflammation response induced by
bacterial endotoxin lipopolysaccharide (LPS) as the stimulus.
All metal complexes were shown to exhibit dose-dependent
inhibitory effects on LPS-induced NO production on both cell
lines. Remarkably, the two iridium complexes 3 and 6 trigger
a full anti-inflammatory response against LPS-induced NO
production, which opens up new avenues for the development
of non-cytotoxic anti-inflammatory drug candidates with
distinct structures and solution chemistry from that of organic
drugs, and as such with potential novel mechanisms of action.
1. Introduction
Inflammation is the body’s natural protective response to
tissue injury caused by physical or chemical stimuli or
invading microbial toxins. Prolonged inflammation can lead
to chronic inflammatory diseases such as asthma, rheumatoid
arthritis, multiple sclerosis, Parkinson’s and Alzheimer’s diseases
and cancer [1–6]. Pro-inflammatory cells, mainly activated
macrophages, produce inflammatory cytokines and other
inflammatory mediators, including overproduction of nitric oxide
(NO) during the process of inflammation [7]. Inflammation can be
initiated and triggered by the stimulation of lipopolysaccharide
(LPS), tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1)
2017 The Authors. Published by the Royal Society under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted
use, provided the original author and source are credited.
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or interferon-gamma (IFN-γ) [8,9]. After exposure to stimulants, the production of inflammatory
cytokines and NO are increased in active macrophages [10]. Therefore, inhibition of NO production is a
major target for anti-inflammatory drug discovery. Nonetheless, there are severe side-effects associated
to current anti-inflammatory drugs and it is of the utmost importance to develop new anti-inflammatory
compounds with less side-effects and different mechanisms of action.
Metal coordination complexes offer a versatile platform for the design of drugs with potential unique
mechanisms of action. The large pool of metal-based drugs arises from the variety of metals, oxidation
states and overall coordination geometry that can be used for their design [11–24]. The number and
types of ligands have a strong influence on the activity of the synthesized metal complex. Although very
ancient, the utilization of metal ions and metal complexes in medicine has been quite recently stimulated
by the clinical success of cisplatin and other platinum(II) anticancer drugs, and by the utilization of
gadolinium complexes as MRI contrast agents and 99 m-technetium radiopharmaceuticals for γ-ray
imaging. The large structural diversity of metal complexes is also an attractive platform for drug design
for other diseases and conditions, including neurodegeneration, microbial and parasitic infections and
inflammation [25–28]. We recently surveyed the significant number of clinical trials that involve metal
compounds, both for therapy and for diagnosis [29]. In this context, it is clear that metal complexes have
the potential to offer an alternative to anti-inflammatory organic drugs. The gold(I) complex auranofin
was approved by the FDA in 1985 as an oral anti-arthritic agent. Although still not fully elucidated, [30]
its mechanism of action is believed to involve the inhibition of cathepsin B [31]. Bismuth complexes are
effective towards a number of diseases, such as syphilis, but the main use of bismuth in therapy is for
the inhibition of Helicobacter pylori [32,33]. Helicobacter pylori is a bacterium that can prevent ulcers from
healing [34]. Owing to the development of antibiotic drug resistance by H. pylori, triple and quadruple
[35] regimens based on two antibiotics, an acid-suppressing agent, and bismuth salts are now being
investigated for the treatment of this bacterium.
Half-sandwich metal complexes of ruthenium, osmium and iridium are a versatile family of
organometallics [36–38]. Their biological properties have raised considerable expectations for the
treatment of cancer since the beginning of the 2000s and are considered as a promising alternative to
platinum-based chemotherapeutics [39–41]. We have recently developed a strong interest in the chemical
and biological properties of electron-deficient half-sandwich complexes. In particular, the 16-electron
(16-e) complexes based on the carborane ligand [Os(η6-p-cymene)(1,2-dicarba-closo-dodecarborane-1,2-
dithiolato)] (1), [Ru(η6-p-cymene)(1,2-dicarba-closo-dodecarborane-1,2-dithiolato)] (2; figure 1) have been
shown to be highly active towards A2780 ovarian cancer cells [42,43]. Their benzene-dithiolato analogues
[Os(η6-p-cymene)(benzene-1,2-dithiolato)] (4), [Ru(η6-p-cymene)(benzene-1,2-dithiolato)] (5, figure 1)
have been recently been shown to exhibit very low reactivity with σ-donor ligands in solution [44]. The
lack of reactivity towards pyridine derivatives in particular was found to be related to the aromaticity
of the five-membered MS2C2 chelate ring by involving sulfur lone pairs in the bonding in the MS2C2
chelate ring.
Here we report an evaluation of the cytotoxicity of electron-deficient metal complexes 1 and 2, their
iridium analogue [Ir(η5-pentamethylcyclopentadiene)(1,2-dicarba-closo-dodecarborane-1,2-dithiolato)]
(3 [45]), and the benzene-dithiol analogues 4, 5 and [Ir(η5-pentamethylcyclopentadiene)(benzene-1,2-
dithiolato)] (6 [44] figure 1) towards RAW 264.7 murine macrophages and MRC-5 fibroblast cells, two
cell lines widely used as in vitro models for the studies of inflammation. The anti-inflammatory activity
of 1–6 was evaluated for both cell lines after inflammation response triggered by bacterial endotoxin
lipopolysaccharide as the stimulus.
2. Material and methods
2.1. Materials
2.1.1. Metal complexes
Metals chloride hydrates were purchased from Precious Metals Online. All other reagents were
obtained from commercial suppliers and used as received. THF was distilled over calcium
hydride. Procedures were performed under nitrogen atmosphere and dried glassware, unless
otherwise stated. The [(η6-p-cymene)MCl(μ-Cl)]2 (M: Ru and Os) and [(η5-C5(CH3)5)IrCl(μ-Cl)]2
dimers were prepared according to literature procedures [46]. [(η5-C5(CH3)5)Ir(S2C6H4)] was
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Figure 1. Molecular structures of the electron-deficient half-sandwich metal complexes studied in this work.
prepared according to literature procedures [47]. Complexes [Os(η6-p-cymene)(1,2-dicarba-closo-
dodecarborane-1,2-dithiolato)] (1), [Ru(η6-p-cymene)(1,2-dicarba-closo-dodecarborane-1,2-dithiolato)]
(2), [Ir(η5-pentamethylcyclopentadiene) (1,2-dicarba-closo-dodecarborane-1,2-dithiolato)] (3), [Os(η6-p-
cymene)(1,2-benzene-1,2-dithiolato)] (4), [Ru(η6-p-cymene)(1,2-benzene-1,2-dithiolato)] (5) and [Ir(η5-
pentamethylcyclopentadiene)(1,2-benzene-1,2-dithiolato)] (6) were prepared according to literature
procedures [47–49].
2.1.2. Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), penicillin and streptomycin,
phosphate-buffered saline (PBS, pH 7.4) and other tissue culture reagents were purchased from
Gibco (Thermo Fisher Scientific, UK). LPS, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide
(MTT) and Griess reagent were purchased from Promega, and all other chemicals were purchased from
Sigma-Aldrich (UK).
2.1.3. Cell culture
RAW 264.7 mouse macrophage cells were obtained from Sigma-Aldrich (UK), and MRC-5 fibroblast
cells were provided by Dr Steve Shnyder, University of Bradford. Cells were cultured in DMEM
supplemented with 10% FBS containing 100 U ml–1 of penicillin and 100 µg ml–1 of streptomycin at
37°C in a 5% CO2 humidified incubator. The solvent used for all biological experiments was 5 : 95 (v : v)
DMSO : water.
2.1.4. Cell viability
Cell viability was assessed using the MTT assay according to the manual. Briefly, cells (2 × 104 cells/well)
were seeded in a 96-well plate and treated with compounds. Following treatment, 20 µl of an MTT
solution (5 mg ml−1 in phosphate-buffered saline) was added to each well and further incubated for
4 h at 37°C. Subsequently, 200 µl of dimethyl sulfoxide (DMSO) was added to each well to solubilize any
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deposited formazon. The optical density (OD) of each well was measured at 490 nm with a microplate
reader (Dynex Technologies).
2.1.5. Quantification of NO production
NO concentration in the cultured medium was determined via the Griess reaction. Specifically, 100 µl of
supernatant from each well was mixed with 100 µl of Griess reagent (1% sulfanilamide in 5% phosphoric
acid and 0.1% naphthylethylenediamine dihydrochloride in water) in a separate 96-well plate. After
an incubation of 15 min at ambient temperature, the optical density was determined at 540 nm with a
microplate reader.
2.1.6. Statistical analysis
All results are from at least three independent experiments and presented as the mean ± s.d (standard
deviation). Significant differences were examined using an analysis of variance (ANOVA) and a Student’s
t-test with SPSS v. 11.0 software (SPSS Inc., Chicago, IL, USA).
2.1.7. Instrumentation
Atmospheric solids analysis probe mass spectroscopy (ASAP-MS) experiments were performed on a
Micromass ZMD mass spectrometer. Mass analysis was performed in positive ionization mode. Settings
are the following: source temperature 400°C, sampling cone 14 V, corona 3.94 kV.
UV–visible spectroscopy was carried out on a PerkinElmer Lambda 35 UV/visible spectrometer or an
Agilent Cary 60 UV–visible spectrophotometer. Quartz cells with two polished sides were used.
3. Results
3.1. Evaluation of the cytotoxicity of complexes 1–6
The cellular viability of RAW 264.7 macrophage cells in the presence of the complexes 1–6 was first
investigated (figure 2a,b). All complexes show slightly reduced cell viability after 24 h of compounds
treatment except complex 6, which did not induce any significant changes in cell viabilities for all tested
concentrations. The cytotoxic effects of complexes 1–5 were found to be dose-dependent (figure 2a).
Interestingly, no cytotoxicity was observed for all compounds after 48 h including 24 h of recovery, and
this was tested for all chosen concentrations (figure 2b).
The cytotoxicity of complexes 1–6 towards RAW 264.7 cells in the presence of LPS (1 µg ml−1) after
24 h (without recovery time; figure 2c) and after 48 h (with 24 h of recovery time; figure 2d) was then
investigated via the MTT assay. After 24 h of treatment by the complexes in the presence of LPS, it was
found that LPS significantly reduces the viability of RAW 264.7 cells (Ctrl: 100.00 ± 0.98 versus LPS:
49.77 ± 1.67). Complexes 1–6 also showed reduced cell viability with a slightly varied response among
them compared to the LPS group (figure 2a,c). Complexes 1 and 2 exhibit a concentration-dependent
inhibition, while the other complexes are concentration-independent. Interestingly, when the cells are
allowed a 24 h recovery, the compounds do not exhibit any cytotoxicity towards RAW 264.7 cells (with
the exception of the slight weak recovery observed with complex 1; figure 2c,d).
The MRC-5 fibroblast cell line was then used to investigate if the effect of complexes 1–6 on cell
viability is cell type-specific. We tested the cell viability after 24 h of incubation with complexes 1–6,
without recovery time (figure 3a) and with a 24 h period of recovery (figure 3b). As previously reported
[42], complex 2 was found to be highly cytotoxic towards MRC-5 cells, and a strong dose-independent
cytotoxic effect was observed, even after 24 h of recovery (figure 3b). Interestingly, the other complexes do
not show a strong cytotoxic effect. In particular, the two osmium complexes 1 and 4 showed a slight dose-
dependent cytotoxicity, while the other complexes have no significant effects on cell viabilities after a 24 h
period of recovery. The exposure of the MRC-5 fibroblast cells to LPS (1 µg ml−1) after 24 h of incubation
(without recovery time; figure 3c) and after 48 h (with 24 h of recovery time; figure 3d) only slightly
induced a reduction in cell viability (Ctrl: 100.00 ± 0.98 versus LPS: 84.97 ± 0.97, n= 12). Complexes 1
and 2 were found to be highly cytotoxic with a weak dose-dependent cytotoxicity, with and without
recovery time. Complexes 3–6 showed no significant cytotoxicity towards MRC-5 fibroblast cells in the
presence of LPS at both 24 and 48 h (see Discussion).
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Figure 2. Effects of complexes 1–6 on the viability of RAW 264.7 (a,b) and LPS-treated RAW 264.7 (c,d) macrophage cells evaluated
by the MTT assay; 24 h (a,c) after treatment by the complexes and with a further 24 h of recovery time (b,d). Detailed data are
included in the electronic supplementary material. All statistical analyses refer to the untreated control. *p< 0.05, **p< 0.01,
***p< 0.001.
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Figure 3. Effects of complexes 1–6 on the viability of MRC-5 fibroblasts (a,b) and LPS-treated MRC-5 fibroblast cells (c,d) evaluated by
the MTT assay; 24 h (a,c) after treatment by the complexes and with a further 24 h of recovery time (b,d). Detailed data are included in
the electronic supplementary material. All statistical analyses refer to the untreated control. *p< 0.05, **p< 0.01, ***p< 0.001.
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Figure 4. Effects of complexes 1–6 onNOproduction in LPS-induced RAW264.7 cells. NO productionwasmeasured by the Griess reaction
assay and expressed as a percentage of the positive control (LPS alone ‘+ −’). The negative control ‘−−’ looks at the NO production
for cells untreated with LPS or any complex. Values are the mean+ s.d. of at least three independent experiments. Detailed data are
included in the electronic supplementary material. All statistical analyses refer to the positive control (LPS alone ‘+ −’). *p< 0.05,
**p< 0.01, ***p< 0.001.
3.2. Evaluation of the anti-inflammatory activity of complexes 1–6
Nitric oxide (NO) production induced by LPS can reflect the degree of inflammation, and a change in
the NO level provides a means to assess the effect of agents on the inflammatory process. To determine
the effects of complexes 1–6 on the LPS-induced production of NO in RAW 264.7 cells, a cell culture
medium was harvested, and the production of NO was measured using the Griess reaction (figure 4).
LPS-induced NO production was significantly decreased by the presence of all complexes in a dose-
dependent manner at all tested concentrations, except for complexes 1 at concentrations of 50 and 100 µM
and 2 at a concentration of 100 µM.
The LPS-induced production of NO was then measured in LPS-induced MCR-5 cells (figure 5).
Similarly, LPS-induced NO production was found to be significantly decreased by the presence of all
complexes in a dose-dependent manner at all tested concentrations, except for complexes 1 and 2 at
a concentration of 100 µM. Complex 1 was found to exhibit no inhibitor effect on LPS-induced NO
production at all tested concentrations. Interestingly, in the case of the iridium complexes 3 and 6, the
decreased NO production reached the level of the control (cells untreated with LPS and complex ‘− −’),
which suggests a full anti-inflammation effect for these two compounds.
3.3. Cell-free investigation of the formation of NO adducts
To confirm the ability of the electron-deficient metal complexes 1–6 to interact with nitric oxide, the
reactivity of complex 2 with NO in solution was studied. Bubbling NO in an acetone solution (2 × 10−3
M, 298 K) of the 16-e complex 2 readily leads to the formation of the 18-e adduct [Ru(η6-p-cymene)(1,2-
dicarba-closo-dodecarborane-1,2-dithiolato)(NO)] ([2-NO]). The addition of the NO ligand is evidenced
by a change of the solution colour from blue to yellow (figure 6), which is in accordance with the
formation of 18-e species for complexes 1–6 [48]. UV–visible absorption spectroscopy also suggests
the formation of the NO 18-e adduct (figure 6), with the dramatic decrease of the absorption band
observed at 632 nm ( = 2100 l mol−1 cm−1; associated to ligand-to-metal charge-transfer transitions
that are commonly observed in 16-electron complexes [49]). ESI-MS analysis of the S,S-coordinated
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Figure 5. Effects of complexes 1–6 on NO production in LPS-induced MRC-5 fibroblast cells. NO production was measured by the Griess
reaction assay and expressed as a percentage of the control (LPS alone ‘+−’). The negative control ‘−−’ looks at the NO production
for cells untreated with LPS or any complex. Values are the mean+ s.d. of at least three independent experiments. Detailed data were
included in the electronic supplementary material. All statistical analyses refer to the positive control (LPS alone ‘+ −’). *p< 0.05,
**p< 0.01, ***p< 0.001.
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Figure 6. UV–visible spectra of complexes 2 and [2-NO] in acetone (10−4 M, 298 K), and pictures of the corresponding solutions.
complexes revealed m/z peaks that correspond to [2-NO] and to the fragmented 16-electron precursor
2 (electronic supplementary material, figure S1).
4. Discussion
Electron-deficient organometallics play a key role as intermediates in organometallic reactions [50].
They are also known to be extremely unstable and most organometallics follow the 18-electron rule.
Some stable coordinatively unsaturated 16-electron (16-e) complexes have been isolated in particular
by the groups of Koelle, Tilley, Suzuki, among others, [51–61], but little is known about their biological
properties. Complexes 1–6 are among the rare examples of stable (in air and in solution) electron-deficient
organometallics. Furthermore, such complexes exhibit unusual chemistry: Although remarkably stable
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as 16-e monomer species (owing to the steric hindrance of the bulky carborane, which prevents
the dimerization of the compounds and the formation of more electronically favoured 18-e species),
[42] these complexes react with σ-donor and π-acceptor ligands to give 18-electron complexes, such
as complexes [Ru/Os(p-cym)(1,2-dicarba-closo-dodecarborane-1,2-dithiolato)(triphenylphosphine)] [48].
When reacted with σ-donor aromatic amines in dichloromethane and chloroform solutions at ambient
temperature, the 16-e blue (Ru) and red (Os) complexes are in equilibrium with their yellow 18-electron
adducts, and the thermal displacement of the equilibrium results in marked thermochromic properties
[62]. Owing to their unusual reactivity in solution, it is anticipated that these 16-e complexes may
possess interesting biological properties, and we recently reported the potent anti-proliferative activity
of complexes 1 and 2 towards A2780 ovarian cancer cells [42]. However, the effects of these complexes
on pro-inflammatory mediators secreted from macrophages and fibroblasts have not been reported. In
the present study, we investigated the cytotoxicity of complexes 1–6 and their anti-inflammatory activity
on lipopolysaccharide (LPS)-activated RAW 264.7 macrophages and MRC-5 fibroblast cells.
4.1. Structure–activity relationships
4.1.1. Inertness, kinetics and electron deficiency: the role of the metal ions
It is clear that some of the complexes studied show distinctive cytotoxic effects in specific cell
lines. In principle, low-spin d6 half-sandwich complexes [(arene)M(X)(Y)(Z)] (arene = benzene or
cyclopentadienyl derivative, (M = Ru, Os or Ir) can be relatively inert towards substitution reactions
and exert their anticancer activity by binding to target sites through outer-sphere interactions [63].
This inertness depends on the specific ligand sets. Inert octahedral metal complexes are emerging as
promising scaffolds for targeting kinase active sites, [64] owing to their rigid and globular shapes, and
high synthetic versatility [65]. Meggers and co-workers have demonstrated that specific RuII, [66] OsII,
[67] RhIII, [68] and IrIII [69] complexes can serve as highly potent (micromolar to nanomolar range) and
selective inhibitors of kinases. Osmium, the heavier congener of ruthenium and a third row transition
metal, commonly exhibits slower kinetics than ruthenium, and is often considered to be relatively
inert. However, it is possible to tune the biochemical reactivity of the arene OsII complexes through an
understanding of their aqueous solution chemistry [63]. We previously reported that the Os complexes
1 and 4 are prompt to react with σ-donor ligands [62]. Ruthenium half-sandwich complexes are usually
more reactive than their osmium counterparts, and their activation via redox pathways or by ligand
substitution can be finely controlled, offering activation only after the complex has reached its target [70].
Although the mechanism of action for the cytotoxicity of complexes 1–6 is unknown and is currently
under investigation, it seems clear that the electron deficiency of such 16-e complexes should allow
interactions with a number of biomolecules en route to or in cells. In this work, we illustrated such
ability by studying the reactivity of complex 2 with NO, which we hypothesize as being the reason for
their anti-inflammatory effects. The absence of cytotoxicity for the iridium complexes 3 and 6 may be
due to a greater inertness and slower kinetics of Ir than Ru and Os analogues. This is in accordance with
our recent study on the reactivity of complexes 4–6 towards σ-donor and σ-donor +π-acceptor ligands
[44]. For example, complexes 5 and 6 are only present as the monomeric 16-e species in solution, while
the less kinetically inert complex 4 is present as both 16-e monomeric and 18-e dimeric structures in
solution. Therefore, the iridium complexes could react with NO (which is an excellent ligand owing to
π-back bonding and steric considerations) but not with large biomolecules, while the more kinetically
active Ru and Os analogues could react not only with NO but also with other targets (e.g. glutathione)
leading to cytotoxicity.
The impact of the nature of the metal ion is evidenced by the fact that the two ruthenium complexes
2 and 5 have a similar effect on the cellular viability of RAW 264.7 macrophage cells at a 20 μM
concentration, while the two osmium complexes 1 and 4 exhibit a slight dose-dependent cytotoxicity
towards MRC-5 fibroblast cells. The most striking result in terms of structure–activity relationships for
the cytotoxicity of the complexes towards the two different cell lines is the observation that the iridium
complexes 3 and 6 do not show any cytotoxic effects at any concentrations.
4.1.2. Amphiphilicity: the role of the non-innocent ligands
One of the main reasons for the intensive research on the synthesis of arene-ruthenium based
anticancer drug candidates is their amphiphilic properties provided by the hydrophobic arene ligand
counterbalanced by the hydrophilic metal centre. Beyond non-classical bonding interactions [71],
dicarba-closo-dodecarboranes possess unusual properties, including high symmetry, remarkable stability
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Table 1. Inhibition of NO production in LPS-induced RAW 264.7 macrophages and MRC-5 fibroblast cells by compounds 1–6. Inhibition
effects are represented as the molar concentration (μM) giving 50% inhibition (IC50) relative to the control. IC50 values were determined
by plotting NO production (percentage of control, y-axis) against the complex× concentrations (x-axis) from the data in figures 4 and 5.
These data represent the average values of three independent experiments.
IC50 values (μM)
complex MCR-5 cells RAW 264.7 cells
1 >100 12.34± 1.19
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 4.52± 1.95 44.99± 4.07
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 22.50± 9.67 70.34± 5.42
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 11.41± 5.92 57.23± 3.36
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 24.63± 7.50 62.50± 4.42
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 25.22± 3.64 43.27± 5.18
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
and high hydrophobicity. Dicarba-closo-dodecarboranes and dicarba-closo-dodecarborane derivatives
have been used as pharmacophores to enhance the hydrophobic interactions of pharmaceutical
compounds with oestrogen and retinoid receptors [72]. The hydrophobicity of complexes 1–3 is,
therefore, expected to be much higher than the one of their benzene analogues. Remarkably, the
cytotoxicity results of complexes 1–6 on both cell lines highlight a dramatic difference of activity between
the two carborane-containing group VIII metal (Ru and Os) complexes 1 and 2 and the other metal
complexes studied in this work. Complexes 1 and 2 show a concentration-dependent inhibition towards
RAW 264.7 cells treated with LPS (1 µg ml−1), while the activity of the other metal complexes 3–6 was
found to be concentration-independent. These same two complexes are the only compounds which
exhibit a significant cytotoxicity effect on MRC-5 fibroblast cells treated with LPS. It seems clear that the
main factor of activity in the two series of electron-deficient half-sandwich metal complexes, therefore,
seems to be the role of the metal ion (because the Ir carborane complex 3 is non-cytotoxic despite
incorporating the dicarba-closo-dodecarborane non-innocent ligand). The effect of the chelating ligand,
although less pronounced than the influence of the nature of the metal ion, is nonetheless of importance,
as exemplified by the dramatic difference of behaviour between the carborane- and benzene-containing
Os and Ru complexes (1 versus 4, and 2 versus 5). Remarkably, the anti-inflammatory activity of the
different complexes follows the same trends of structure–activity relationship as the anti-proliferative
one. Carborane- and benzene-containing Ru and Os complexes (1 versus 4, and 2 versus 5) show stark
differences in their abilities to decrease the LPS-induced NO production. Finally, it should be noted that
all complexes are neutral and have similar solubilities in the mixture 5 : 95 v : v DMSO : water used for
the biological testing.
4.1.3. Anti-proliferative activity
Similarly to the cytotoxicity results, the two iridium complexes 3 and 6 display a remarkable difference
of behaviour compared to their ruthenium and osmium analogues. Both iridium complexes, in addition
to being non-cytotoxic, possess the ability to reduce the NO production to the level of the control assay
(cells ‘− −’, untreated with LPS and complex). This indicates that these two compounds are not toxic and
offer a full anti-inflammation protection to the cells. Some differences of anti-inflammatory activity are
noticeable depending on the cell types, particularly in terms of inhibition of LPS-induced NO production.
Although all complexes displayed dose-dependent inhibitory effects on LPS-induced NO production on
both cell lines, the compounds were found to have greater potential to inhibit NO production on MCR-
5 cells regardless of the metal ions and ligands, than on RAW 264.7 cells, as evidenced by the molar
concentration values (μM) giving 50% inhibition (IC50) relative to the control in table 1.
5. Conclusion
The cytotoxicity and anti-inflammatory effects of six electron-deficient half-sandwich metal complexes
of ruthenium, osmium and iridium towards LPS-induced RAW 264.7 macrophages and MRC-5
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fibroblast cells were investigated. The six metal complexes were shown to exhibit dose-dependent
inhibitory effects on LPS-induced NO production on both cell lines. Remarkably, the two iridium
complexes [Ir(η5-pentamethylcyclopentadiene)(1,2-dicarba-closo-dodecarborane-1,2-dithiolato)] (3) and
[Ir(η5-pentamethylcyclopentadiene)(benzene-1,2-dithiolato)] (6) were found to be non-cytotoxic and to
trigger a full anti-inflammatory response towards LPS-induced NO production. We hypothesize that the
electron-deficient configuration at the metal centre allows binding of the ligand NO to the metal ion.
The extent of such binding and its implication towards the anti-inflammatory mechanisms of action
of complexes 1–6 will be investigated in future work. The anti-inflammatory effect of non-cytotoxic
16-e complexes has the potential to be useful in the treatment of severe infectious diseases which trigger
inflammation and fibrosis at the end stage, like SARS (severe acute respiratory syndrome), [73] which
is a fatal disease without effective antiviral agents available now. Another disease enduring similar
pathologic changes is chronic liver infectious disease, like hepatitis C, which also has poor prognosis
without proper treatment available. Therefore, the two iridium compounds have the potential to be
useful in controlling the progression of these severe diseases; in comparison, cortisone has similar
anti-inflammatory effect but causes side effects such as osteonecrosis of the femoral head at high dosage.
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